A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

NCT06626919 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Diseases
Neuromuscular Manifestations
Autoimmune
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Myasthenia Gravis
Muscle Weakness

Interventions

BIOLOGICAL: anito-cel
DRUG: Standard Lymphodepletion regimen

Sponsor

Arcellx, Inc.